BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 19004037)

  • 1. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum soluble CD40 levels in patients with systemic sclerosis.
    Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
    Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
    J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum soluble OX40 in patients with systemic sclerosis.
    Komura K; Yoshizaki A; Kodera M; Iwata Y; Ogawa F; Shimizu K; Wayaku T; Yukami T; Murata M; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2359-62. PubMed ID: 18843780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
    Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
    J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
    Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
    Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.
    Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Usui A; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 Aug; 36(8):1657-62. PubMed ID: 19531747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score.
    Dziadzio M; Smith RE; Abraham DJ; Black CM; Denton CP
    Rheumatology (Oxford); 2005 Dec; 44(12):1518-24. PubMed ID: 16159952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum interleukin 23 in patients with systemic sclerosis.
    Komura K; Fujimoto M; Hasegawa M; Ogawa F; Hara T; Muroi E; Takehara K; Sato S
    J Rheumatol; 2008 Jan; 35(1):120-5. PubMed ID: 18085738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patients.
    Arakawa H; Jinnin M; Muchemwa FC; Makino T; Kajihara I; Makino K; Honda N; Sakai K; Fukushima S; Ihn H
    Exp Dermatol; 2011 Sep; 20(9):764-6. PubMed ID: 21615510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
    Carulli MT; Handler C; Coghlan JG; Black CM; Denton CP
    Ann Rheum Dis; 2008 Jan; 67(1):105-9. PubMed ID: 17604287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
    Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
    Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
    Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
    Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
    Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of insulin-like growth factor-I and insulin-like growth factor binding proteins during thioacetamide-induced liver cirrhosis in rats.
    Novosyadlyy R; Dargel R; Scharf JG
    Growth Horm IGF Res; 2005 Oct; 15(5):313-23. PubMed ID: 16098781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.